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Abstract
We investigated whether immune responses induced by immunization with plasmid DNA are restricted predominantly to immunodominant CD8+
T cell epitopes, or are raised against a breadth of epitopes including subdominant CD8+ and CD4+ T cell epitopes. Site-directed mutagenesis was
used to change one or more primary anchor residues of the immunodominant CD8+ T cell epitope on the Plasmodium yoelii circumsporozoite
protein, and in vivo protective efficacy and immune responses against defined PyCSP CD8+ and/or CD4+ epitopes were determined. Mutation of the
P2 but not P9 or P10 anchor residues decreased protection and completely abrogated the antigen-specific CD8+ CTL activity and CD8+ dependent
IFN- responses to the immunodominant CD8+ epitope and overlapping CD8+/CD4+ epitope. Moreover, mutation deviated the immune response
towards a CD4+ T cell IFN- dependent profile, with enhanced lymphoproliferative responses to the immunodominant and subdominant CD4+
epitopes and enhanced antibody responses. Responses to the subdominant CD8+ epitope were not induced. Our data demonstrate that protective
immunity induced by PyCSP DNA vaccination is directed predominantly against the single immunodominant CD8+ epitope, and that although
responses can be induced against other epitopes, these are mediated by CD4+ T cells and are not capable of conferring optimal protection against
challenge.
© 2006 Elsevier Ltd. All rights reserved.
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. Introduction
Immunization with radiation-attenuated Plasmodium spp.
onfers sterile protection against sporozoite challenge in both
uman and animal models (reviewed in Hoffman et al., 2002). In
ice, CD8+ T cells have been implicated as critical effector cells
n this sporozoite-induced protective immunity. In vitro, MHC-
estricted and Ag-specific elimination of Plasmodium yoelii
nfected hepatocytes from in vitro culture by CD8+ CTL has
een demonstrated (Hoffman et al., 1989). In vivo, the protective
mmunity induced by immunization of BALB/c mice with irra-
iated P. yoelii sporozoites can be abrogated by in vivo depletion
f CD8+ T cells but not CD4+ T cells (Weiss et al., 1988), and
doptive transfer of CD8+ CTL against a single epitope on the
. yoelii circumsporozoite protein (PyCSP) can protect against
porozoite-induced malaria in the absence of other parasite-
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pecific immune responses (Rodrigues et al., 1991; Weiss et
l., 1992). Evidence that CD8+ T cells are also critical in pro-
ective immunity against Plasmodium falciparum in humans has
ccumulated from studies of humans immunized with irradiated
porozoites or naturally exposed to malaria (reviewed in Aidoo
nd Udhayakumar, 2000; Doolan et al., 1996b). In addition to
D8+ CTL, IFN- has been demonstrated as another critical
ffector mechanism mediating the inhibition of pre-erythrocytic
orms of the parasite in the liver (Ferreira et al., 1986).
Previous studies have established that the protective immu-
ity induced in BALB/c mice by immunization with a plasmid
NA construct encoding the PyCSP is absolutely dependent
pon CD8+ but not CD4+ T cells (Doolan et al., 1996a; Sedegah
t al., 1994) and IFN- (Doolan et al., 1996a). A single immun-
dominant CD8+ CTL epitope located at residues 280–288
SYVPSAEQI) has been identified on the PyCSP (Weiss et
l., 1990). In vitro CTL activity and IFN- production spe-
ific for this minimal nine amino acid epitope correlate with
n vivo protective immunity in BALB/c mice (Sedegah et al.,
994). In addition, an epitope located at residues 59–79 of
he PyCSP (YNRNIVNRLLGDALNGKPEEK) was shown to
rime for specific T cell proliferation (Del Giudice et al., 1990)
nd CD8+ mediated elimination of P. yoelii infected hepatocytes
rom in vitro culture (Renia et al., 1991). Finally, immuniza-
ion of mice with a multiple antigenic peptide containing the Th
pitope PyCSP 57–70 (KIYNRNIVNRLLGD) induces T cell
roliferation and a CTL response capable of eliminating infected
epatocytes in vitro, and confers partial protection against sporo-
oite challenge (Franke et al., 1997). The CTL response is
pecific for a subdominant CD8+ T cell epitope mapped to
esidues 58–67 (IYNRNIVNRL) that is recognized following
mmunization with MAP (57–70) but not following immuniza-
ion with either the whole organism (irradiated sporozoite) or
hole Ag (PyCSP plasmid DNA).
To mediate protective immunity, CD8+ T cells must recog-
ize parasite-derived peptides that are presented on the surface of
nfected hepatocytes in association with class I MHC molecules
nd either directly or indirectly destroy the infected hepatocyte,
r inactivate the intra-hepatic parasite. Since sporozoites and
erozoites in circulation are extracellular, and mature human
rythrocytes do not express class I MHC molecules on their sur-
ace, infected hepatocytes are considered the likely target of
D8+ T cells against Plasmodium spp. (Good et al., 1988).
ccordingly, there have been major efforts to develop pre-
rythrocytic stage vaccines that induce protective CD8+ T cells.
It is well established that T cells do not recognize foreign Ag
irectly, but instead recognize a form of the Ag presented in the
ontext of class I or class II molecules encoded by genes within
he MHC (Zinkernagel and Doherty, 1979; Bjorkman et al.,
987a,b; Jardetzky et al., 1991; Saper et al., 1991). A stringent
ize requirement for peptide binding to class I MHC molecules
as been defined (Cerundolo et al., 1991) and it is apparent
hat the different class I molecules require a specific combina-
ion of two main “anchor” residues crucial for binding within
heir peptide ligands, typically at position 2 and the C-terminus
Rotzschke and Falk, 1991). Binding of these primary anchor
ide chains in specific MHC pockets constrains the conforma-
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ion of class I-bound peptides at both ends but leaves the center
elatively free to adopt a conformation that optimizes secondary
nchor and other interactions with the MHC molecule.
Using the well established P. yoelii-BALB/c rodent model of
re-erythrocytic stage immunity, we have investigated the effect
hat mutating one or more of the primary anchor residues of
he single immunodominant PyCSP 280–288 CD8+ CTL epi-
ope has on immunogenicity and protection against P. yoelii
porozoite challenge induced by DNA vaccination. TheP. yoelii-
ALB/c model is considered a good model for P. falciparum in
umans and to have a negative predictive value for potential
uccess in the clinic, in that vaccine technologies or strategies
hat do work in this model may not necessarily work in humans
ut vaccines that do work in humans do work in this model.
ased on the previously described Kd peptide-binding motif
Haskins et al., 1984), positions 2 (Y281) and 9 (I288) represent
he primary anchor residues of the immunodominant PyCSP
TL epitope. However, position 10 (L289) may potentially sub-
titute for position 9 (I288) as the C-terminus primary anchor
esidue. Previous studies (Weiss et al., 1992) have demonstrated
hat truncation of the epitope to remove position Y281 abro-
ates the CTL response. Herein, site-directed mutagenesis was
mployed to specifically mutate one or more of positions 2
Y281), 9 (I288) and 10 (L289) to alanine, where the small size
f the latter amino acid would not be expected to interfere
ith peptide binding to the MHC. We determined whether this
pitope is absolutely required for the CD8+ T cell mediated
rotection in BALB/c mice, and whether immunization with
lasmid DNA encoding the PyCSP would preferentially induce
rotective immune responses directed against this epitope. Our
tudies establish that protective immunity induced by PyCSP
NA vaccination is directed predominantly against the single
mmunodominant CD8+ epitope, and that although responses
an be induced against other epitopes, these are mediated by
D4+ rather than CD8+ T cells and are not capable of conferring
ptimal protection against parasite challenge.
. Materials and methods
.1. Oligonucleotide primers
Oligonucleotide primers (Integrated DNA Technologies Inc.,
aralville, IA) were designed for site-directed mutagenesis to
pecifically change amino acid Y281 representing the position 2
rimary anchor residue of the previously defined 10-mer CTL
pitope PyCSP280–289 (SYVPSAEQIL, encoded by TCA TAT
TC CCA AGC GCG GAA CAA ATA CTA) (Weiss et al., 1990)
rom tyrosine to alanine (888 AAT GGT AAT AAT AAT GAA
AT TCA GCT GTC CCA AGC GCG GAA 929, restriction
nzyme sites underlined, mutated positions in bold; translated
s 273 NGNNNEDSYVPSAE 286, immunodominant CTL epi-
ope underlined), and amino acids I288 and L289 representing
ositions 9 and 10 primary anchor residues from isoleucine and
eucine, respectively, to alanine (915 GTC CCA AGC GCG GAA
AA GCA GCA GAA TTC GTT AAA CAG ATA AG 958;
ranslated as 282 VPSAEQILEFVKQI 295). Thus, the TAT codon
ncoding the P2 anchor residue Y281 was mutated to GCT (Ala),
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nd the codons encoding the P9 I288 (ATA) or P10 L289 (CTA)
nchor residues were both mutated to GCA (Ala). For each
utation, two primers containing the desired mutation, each
omplementary to opposite strands of the nkCMVintPolyli/CSP
lasmid, were synthesized. Primers 1 (forward) and 2 (reverse)
42 bp) incorporated a PvuII restriction enzyme site to con-
rm the mutagenesis of position 2. Primers 3 (forward) and 4
reverse) (44 bp) incorporated an EcoRI restriction enzyme site
o confirm the mutagenesis of positions 9 and 10. Primers were
esigned so that the thymidine (T) and guanidine (G) content was
pproximately 40%, with melting temperatures approximately
0 ◦C greater than the extension temperature (68 ◦C) to encour-
ge binding of the primers to the DNA template. Mutations were
apped to the middle of the primer sequence.
.2. Site-directed mutagenesis of plasmid DNA
Four DNA plasmids were constructed. The DNA construct
ncoding the non-mutated PyCSP gene (nkCMVintPolyli/CSP)
as been described previously (Sedegah et al., 1994). This con-
truct was mutated at position Y281 representing the position 2
rimary anchor residue of the previously defined CTL epitope, or
t positions I288 and L289 representing positions 9 and 10 primary
nchor residues respectively, or at positions Y281, I288 and L289
epresenting positions 2, 9 and 10 primary anchor residues. Site-
irected mutagenesis was carried out using the QuikChangeTM
Stratagene, La Jolla, CA) as described by the manufacturer.
he cycling parameters outlined in the mutagenesis kit proto-
ol were optimized for the specific primer-DNA combinations
s one cycle at 95 ◦C for 30 s, followed by 18 cycles at 95 ◦C
or 30 s, 55 ◦C for 1 min, 60 ◦C for 2 min, and then 68 ◦C for
2 min, using 15 ng DNA template and a DNA Thermal Cycler
Perkin-Elmer Cetus, Norwalk, CT, USA). For position 2 muta-
enesis, or positions 9 and 10 mutagenesis, the template was
he nkCMVintPolyli/CSP plasmid. For positions 2, 9 and 10
utagenesis, the template was the nkCMVintPolyli/CSP plas-
id mutated at positions 9 and 10, and cycled with primers 1 and
. Oligonucleotide primers were extended during the tempera-
ure cycling by the action of Pfu DNA polymerase and copies
f the plasmid incorporating the desired mutation(s) generated
y linear amplification. The methylated non-mutated parental
NA template was digested by treatment with DpnI endonu-
lease, resulting in selection of synthesized DNA containing
he desired mutation(s). DNA was then transformed into Epi-
uran Coli XL1-Blue or DH10B ultracompetent cells by heat
hock. Plasmid DNA from transformed colonies was prepared
sing the QIAprep Spin Plasmid kit (QIAGEN Inc., Chatsworth,
A) and digested with PvuII and/or EcoRI to confirm the
utagenesis.
.3. Sequencing of DNA constructs
The DNA sequence of each construct was determined
rom both strands using the ABI PRISMTM Ready Reaction
ye DeoxyTM Terminator Cycle Sequencing kit (Perkin-Elmer
orporation, Norwalk, CT), under conditions described by
he manufacturer. Sequencing primers mapped to the vector
o
S
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NA sequence adjacent to the polycloning site, or within
he PyCSP gene. Large-scale preparations of the DNA con-
tructs were purified by standard alkaline lysis followed by
esium chloride gradient centrifugation (Hedstrom and Doolan,
002).
.4. In vitro expression
Expression of the encoded gene was confirmed in vitro
y transient transfection of UM449 cells (kindly provided
y Vical Inc., San Diego, CA) or P815 mastocytoma cells
American Type Culture Collection, TIB 64) with 2.5g of
IAGEN purified plasmid DNA and 10l lipofectin (Gibco
RL), as described by the manufacturer. Subsequent anal-
sis of the UM449 cell lysate was done by Western blot
sing the PyCSP specific mAb NYS1 (Charoenvit et al.,
987). Subsequent analysis of the P815 transfected cells was
one by the indirect fluorescent antibody test (IFAT) using
YS1 as the primary Ab and FITC-conjugated goat-anti-mouse
s the secondary Ab (Kierkegaard and Perry, Gaithersburg,
D).
.5. Mice and parasites
Female 5–8-week-old BALB/cByJ mice were obtained from
he Jackson Laboratory, Bar Harbor, ME. P. yoelii (17× NL
on-lethal strain, clone 1.1) was maintained by alternating pas-
ages of the parasites in Anopheles stephensi mosquitoes and
D-1 mice. P. yoelii sporozoites were obtained 14 days after
n infectious blood meal by hand-dissection of P. yoelii 17×
L infected mosquito glands in M199 medium containing 5%
ormal mouse serum (Rockland, Gilbertsville, PA). The exper-
ments reported herein were conducted in compliance with the
nimal Welfare Act and in accordance with the principles set
orth in the “Guide for the Care and Use of Laboratory Animals”,
nstitute of Laboratory Animal Resources, National Research
ouncil, National Academy Press, 1996 (Office of Laboratory
nimal Welfare Assurance #A4117-01; AAALAC Accredita-
ion Unit# 00847).
.6. Immunizations
Mice were immunized 3 times at 3-week interval i.m. in each
ibialis anterior muscle with 50g of each plasmid DNA con-
truct in a total volume of 50l saline, or unmodified empty
lasmid. Two weeks after the third immunization, mice were
hallenged by tail-vein injection with infectious sporozoites.
wo, 4 or 7 weeks after the third immunization, mice were
acrificed for T cell studies.
.7. Synthetic peptides
Synthetic peptides representing each of the non-mutated
r mutated T cell epitopes, SYVPSAEQIL, SAVPSAEQIL,
YVPSAEQAA, and SAVPSAEQAA were synthesized com-
ercially (Research Genetics, Huntsville, AL). Peptides were
ssessed for affinity of binding to purified MHC molecules
2238 C. Doban˜o et al. / Molecular Immunology 44 (2007) 2235–2248
Table 1
PyCSP epitope sequences and H-2Kd binding affinity
Peptide sequences Length Comments Kd IC50 (nM)
SYVPSAEQI 9 PyCSP 280–288: dominant CTL epitope (9-mer) 2.2
SYVPSAEQIL 10 PyCSP 280–289: dominant CTL epitope (10-mer) 280
SAVPSAEQI 9 PyCSP 280–288: mutated at P2 >10,000
SYVPSAEQAA 10 PyCSP 280–288: mutated at P9, P10 8,600
SAVPSAEQAA 10 PyCSP 280–288: mutated at P2, P9, P10 >10,000
SYVPSAEQILEFVKQI 16 PyCSP 280–295: dominant CD4+/CD8+ T cell epitope (nested dominant CD8+ T cell epitope) 463
IYNRNIVNRL 10 PyCSP 58–67: subdominant CD8+ T cell epitope 16
KIYNRNIVNRLLGD 14 PyCSP 57–70: dominant CD4+ T cell epitope (nested subdominant CD8+ T cell epitope) 8,250
YNRNIVNRLLGDALNGKPEEK 21 PyCSP 59–79: subdominant CD4+ T cell epitope 1,104
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Primary anchor residues are indicated in bold type, underlined.
n vitro (Epimmune Inc., San Diego, CA). Additional pep-
ides used for in vitro stimulation and for antigen presenting
ell (APC) sensitization in the T cell assays are detailed in
able 1.
.8. CTL assay
Spleen cells from mice collected after the third immuniza-
ion were incubated at a concentration of 5 × 106 cells in 2 ml
f RPMI 1640 medium supplemented with 10% heat inacti-
ated FBS (Sigma), 10 mM HEPES, 2 mM l-glutamine (Gibco),
0M 2-ME, 50 U/ml penicillin, and 50 U/ml streptomycin
Gibco) (cRPMI) in a 24-well plate, in the presence of 2.5M
f synthetic peptide PyCSP 280–295 containing the previ-
usly defined 9/10-mer CTL epitope, or in the presence of the
inimal PyCSP 280–288 peptide. Alternatively, spleen cells
ere stimulated in vitro at a responder:stimulator ratio (num-
er of responder spleen cells stimulated in vitro per added
ransiently transfected stimulator cell) of 50:1 with irradiated
HC-matched (H-2d) P815 mastocytoma cells (American Type
ulture Collection, TIB 64) or MHC-mismatched (H-2b) EL4
ymphoma cells (ATCC TIB 39) transiently transfected 48 h pre-
ious with 2.5g of non-mutated or mutated plasmid DNA and
0l lipofectin (Gibco BRL), as described by the manufacturer;
ells were incubated at a concentration of 30 × 106 cells per
0 ml volume of cRPMI in an upright 25 cm2 Roux flask. In both
ases, Rat T-stim (Collaborative Biomedical Products) (2.5%)
as added at 48 h as a source of IL-2. After 7 days of incubation,
ells were used as effectors in a standard 6 h chromium release
ssay. Target cells were P815 or EL4 cells transiently trans-
ected with non-mutated or mutated plasmid DNA 48 h previous,
r pulsed overnight with PyCSP 280–288, PyCSP 280–295,
yCSP 57–50, an unrelated control peptide, or no peptide, and
abeled with 100Ci 51Cr (sodium chromate solution). Expres-
ion of the transfected cells was confirmed by IFAT analysis
sing the PyCSP mAb NYS1 (data not presented). Percent lysis
as determined as [(experimental release − medium control
elease)/(maximum release − medium control release)] × 100.
ercent specific lysis (net) was determined as % lysis (test) − %
ysis (control). Responses were classified as positive if percent
pecific lysis [% lysis (test) − % lysis (control)] was greater than
0%.
w
2
d
f.9. In vitro depletions of effector cells
MACS magnetic beads (Miltenyi Biotec, Auburn, CA)
ere used to deplete CD4+, CD8+, or CD56+ cells from
ouse splenocytes, in accordance with manufacturer’s instruc-
ions. MACS CD4 (L3T4), CD8a (Ly-2) and anti-NK (DX5)
icroBeads (Miltenyi Biotec) positive selection columns were
sed to specifically remove selected cell populations from
plenocyte suspensions immediately prior to IFN- ELIspot
r intracellular cytokine staining assays. The depleted flow-
hrough portions were used as effector cells in the in vitro T
ell studies to evaluate the requirement for CD4+ T cell, CD8+
cell and NK cell in IFN- production. Efficiency of depletion
as >95–99% in all cases.
.10. Interferon γ ELIspot
Multiscreen MAHAS 4510 plates (Millipore, Bedford, MA)
ere coated with 50l/well of sterile carbonate/bicarbonate
uffer containing 10g/ml of anti-murine IFN- (R4, Pharmin-
en, San Diego, CA) and incubated overnight at room
emperature. Plates were washed twice with 200l/well RPMI
edium and twice with cRPMI medium containing peni-
illin/streptomycin, l-glutamine and 10% FBS, and incubated
ith 200l/well of cRPMI medium in 5% CO2 at 37 ◦C for at
east 3 h. After blocking, the plates were washed once more with
RPMI before the addition of effector cells and APCs. A20.2J
e.g., ATCC clone HB-98) and P815 (ATCC TIB 64) APCs
ere washed once with cRPMI, incubated at 5 × 106 cells/ml
ith or without PyCSP peptide (10g/ml) for 1 h at 37 ◦C in
% CO2, and irradiated in a 137Cs gamma irradiator (A20.2J at
6,000 rads and P815 at 10,000 rads). Next, APCs were washed
hree times with cRPMI, diluted to 1.0 × 106 cells/ml (P815)
r 1.5 × 106 cells/ml (A20.2J) in cRPMI. To obtain spleno-
ytes, immunized mice were sacrificed 2, 4 or 7 weeks after
he boost (three mice/group), their spleens removed to a ster-
le tissue screen and ground with glass pestle into a sterile
etri dish using cRPMI. The spleen cell suspensions were
ashed three times, counted and diluted to 5 × 106 cells/ml and
.5 × 106 cells/ml. Effector cells and APCs were plated in qua-
ruplicates at 100l/well, and incubated in 5% CO2 at 37 ◦C
or 36 h. Plates were washed three times with PBS followed
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y four times with PBS-T (PBS 0.05% Tween20). 100l/well
f biotinylated anti-IFN- (XMG1.2, Pharmingen, San Diego,
A) at 2g/ml in PBS-T were added to the plates and incubated
vernight at 4 ◦C. Plates were washed six times with PBS-T
nd 100l/well peroxidase conjugated streptavidin (Kirkekaard
Perry, Gaithersburg, MD) was added at 1:800 dilution in
BS-T. After 1 h incubation at room temperature, plates were
ashed six times with PBS-T followed by three times with
BS alone, and developed with DAB reagent (Kirkekaard &
erry, Gaithersburg, MD) according to manufacturer’s instruc-
ions. After 15 min, the plates were rinsed extensively with dH2O
o stop the colorimetric substrate, dried and stored in the dark.
pots were counted with a KS ELIspot reader (Carl Zeiss Vision,
ermany).
.11. Intracellular cytokine staining and FACS analysis
A20.2J cells were pulsed with or without 10M PyCSP
eptide (10g/ml) for 1 h at 37 ◦C in 5% CO2, and irradiated
s above. Then, 100l/well of spleen cells (5 × 106 cells/ml)
nd 100l/well A20.2J cells (1.5 × 106 cells/ml) pulsed with
r without PyCSP peptide were incubated in duplicates in U-
ottom 96-well plates (Costar) in the presence of 1M Brefeldin
(GolgiPlugTM, Pharmingen, San Diego, CA) in 5% CO2 at
7 ◦C for 16 h. Plates were spun at 1200 rpm for 5 min, the
upernatant flicked, and the cell pellet resuspended by gentle vor-
exing. Cell surface markers were stained with 0.3–0.5l/well
f anti-CD8-APC, anti-CD4-PERCP, anti-DX5-FITC or anti-
D62L-FITC Abs (Pharmingen, San Diego, CA) in a final
olume of 100l in FACS wash. Plates were incubated with a
ombination of three Abs on ice in the dark for 20 min. After the
urface staining, cells were washed with FACS wash twice, gen-
ly resuspended, and incubated with 90l of Cytofix/Cytoperm
uffer (Pharmingen, San Diego, CA) for 20 min on ice in the
ark. Next, cells were washed with 100l of Perm/Wash buffer
nd intracellular IFN- or TNF- were stained with 0.5l/well
f anti-IFN--PE or anti-TNF--PE Abs (Pharmingen, San
iego, CA) in a final volume of 100l in Perm/Wash buffer.
fter 20 min incubation on ice in the dark, cells were washed
wice with Perm/Wash, once with FACS wash, resuspended in
00l of FACS wash and stored at 4 ◦C prior to analysis. The
fficiency of anti-CD4+, anti-CD8+ and anti-DX5 (NK cells)
b depletion in vivo and in vitro, as well as peptide-specific
FN- and TNF- intracellular production, was determined in a
our-color FACSCaliburTM (Becton Dickinson Immunocytom-
try Systems, San Jose, CA) with CellQuest software.
.12. Lymphocyte proliferation
Spleen cells from immunized mice were cultured in qua-
ruplicate at a concentration of 125, 250 or 500 × 103 cells in
.2 ml of cRPMI medium in a flat-bottom 96-well tissue culture
late in the presence of peptide (concentrations ranging from
.625 to 40g/ml) without peptide, or with mitogen (ConA at
g/ml) for 5 days. Wells were then pulsed with 1.0Ci 3H-
ethyl thymidine (Dupont NEN) overnight, and uptake assessed
y liquid scintillation spectroscopy (Beckman LS6800). Results
v
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ere expressed as a stimulation index (S.I.) (cpm sample/cpm
ontrol without peptide).
.13. Antibody response
Mice were bled for serum approximately 2 weeks after each
mmunization. Abs were assessed by ELISA against recom-
inant PyCSP protein (0.1g/ml), as previously described
Charoenvit et al., 1987), either individually or pooled as indi-
ated in the text.
.14. Cytokine analysis
Individual sera from experimental mice (n = 12–13 per group)
ollected 14 days post last immunization, immediately prior to
hallenge, were assayed in duplicate using the Pierce Searchlight
ultiplexed Sample Analysis Service (Pierce Biotechnology
nc., Woburn, MA) against a custom 16-plex mouse panel com-
rising the following cytokines: IFN-, TNF-, IL-1, IL-1,
L-2, hIL-2r, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-13,
L-17, IL-18, and hIL-15.
.15. In vivo depletions
Anti-CD4+ mAb GK1.5 (rat IgG2a) (Dialynas et al., 1983)
nd anti-CD8+ mAb 2.43 (mouse IgG2a) (Sarmiento et al.,
980) were obtained from ATCC (TIB207, TIB210). Anti-IFN-
mAb XMG-6 (rat IgG1) (Cherwinski et al., 1987) was kindly
rovided by Dr. F. Finkelman. All Igs were purified from ascites
Harlam Bioproducts for Science, Indianapolis, IN) by 50%
mmonium sulphate precipitation and final Ab concentrations
etermined by OD. Cell depletions were done immediately prior
o the evaluation of liver-stage protection. For CD8+ T cell deple-
ion, mice received a single i.p. dose of 0.5 mg/0.1 ml of mAb
.43 on days −3, −2, and −1. For CD4+ T cell or IFN- deple-
ion, mice received a single i.p. dose of 1.0 mg/0.1 ml of mAb
K1.5 or XMG-6, respectively, on days −3, −2, and −1. The
ontrol group received no treatment. In vivo depletion regimes
eported here are routinely used in our laboratory and have been
esigned so as to ensure that the treatments are effective and
eproducible (data not presented) (Doolan and Hoffman, 1999).
.16. In vivo protection
For evaluation of sterile protection at the blood-stage, infec-
ious sporozoites were diluted to a final concentration of 50
porozoites per 0.2 ml. Mice were challenged by tail-vein injec-
ion and giemsa-stained blood smears were examined on days
–14, up to 50 oil-immersion fields being scanned for parasites.
rotection was defined as the complete absence of blood-
tage parasitemia. For evaluation of partial protection at the
iver-stage, sporozoites were diluted to a final concentration
f 50,000 sporozoites per 0.2 ml and injected i.v. in the tail
ein. Forty-two hours after challenge, mice were euthanized and
he livers collected in RNAlaterTM solution (Ambion, Austin,
X), homogenized in Trizol® (Invitrogen, Carlsbad, CA), and
tored at −80 ◦C. Parasite RNA was extracted and quantified
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y TaqMan® quantitative real time PCR, as described else-
here (Witney et al., 2001). An estimate of P. yoelii 18S rRNA
plasmid equivalents” and mouse GAPDH (housekeeping gene)
plasmid equivalents” were derived from the Ct (threshold cycle)
easured for each PCR target for each unknown sample (Witney
t al., 2001).
.17. Statistical analysis
Mean Ab titers were expressed as OD units 0.5 (serum dilu-
ion corresponding to an OD value of 0.5) and analyzed by the
-test of independent samples. Serum cytokines were reported
s median and percentiles (25% and 75%) and analyzed by the
on-parametric Mann–Whitney U-test. To assess blood stage
rotection, comparison between groups was performed by the
hi square test (two-tailed) (EpiInfo, CDC). To assess liver stage
rotection, quantitative parasite burden data was expressed as the
atio of P. yoelii 18S rRNA plasmid equivalents over the mouse
APDH RNA plasmid equivalents for each sample (Witney et
l., 2001). Assessment of statistical significance was performed
y Student’s unpaired t testing on log (base2) transformed data.
ignificance was defined at the 5% level.
. Results
.1. In vitro and in vivo expression of plasmid DNA
onstructs
IFAT analysis of transfected P815 cells confirmed the in vitro
xpression of all non-mutated and mutated plasmid DNA con-
tructs (data not presented). The in vitro expression of the DNA
onstructs was reconfirmed by analysis of transiently transfected
M449 cells by Western blot (data not presented).
a
C
P
ig. 1. Antigen-specific, MHC-restricted CTL activity to immunodominant CD8+ and
yCSP plasmid DNA. Effector cells were splenocytes from BALB/c mice immuniz
fter the third immunization (n = 3 per group, pooled), and cultured in vitro for 6 days
cell epitope (residues 280–288) or the overlapping CD8+/CD4+ T cell epitopes (pe
r MHC-mismatched EL4 cells (not shown) target cells pulsed with the 280–288 or 2nology 44 (2007) 2235–2248
.2. Binding affinity of non-mutated and mutated peptides
The capacity of synthetic peptides representing the non-
utated (native) and mutated epitopes to bind in vitro to the
HC molecule was quantitated as a coefficient of binding (Kd).
inding efficiencies for the respective peptides are reported in
able 1. Kd values of 1–50 nM are associated with high bind-
ng affinity, 50–500 nM with intermediate binding affinity, and
500 nM with little or no binding. Previous studies (Sette et al.,
994) have revealed an association between binding affinity and
mmunogenicity.
.3. Effect of mutations on induction of CTL to defined
eptide epitopes or intact protein
Spleen cells of mice immunized with non-mutated PyCSP
NA stimulated in vitro with either the PyCSP 280–288
r PyCSP 280–295 synthetic peptides containing the non-
utated 9/10-mer CTL epitope induced robust Ag-specific CTL
esponses directed against the immunodominant CD8+ T cell
pitope (residues 280–288) (Fig. 1 and Table 2). Results obtained
ith splenocytes harvested at different time points (2, 4 or 7
eeks) post third immunization were consistent between time-
oints. Effectors failed to recognize the epitope mutated at
ositions P2, P9 and P10, but did recognize the epitope with
he original residue at P2 but mutated residues at P9 and P10
Table 2). These data show that the primary P2 N-terminal
nchor, but not the P9 or P10 C-terminal anchors, are critical
or CTL recognition. Consistent with previous data (Franke et
l., 1997), these effectors failed to recognize the subdominant
D8+ T cell epitope at residues 58–67 (Table 2).
Immunization of mice with PyCSP DNA containing the P2,
9/P10 mutations, the P2 mutation, or the P9/P10 mutations, did
CD8+/CD4+ epitopes induced by immunization with non-mutated and mutated
ed with non-mutated or P2, P9/P10 mutated PyCSP DNA, harvested 7 weeks
in the presence of synthetic peptides representing the immunodominant CD8+
ptide 280–295). Effectors were then assayed against MHC-matched P815 cells
80–295 peptides, or not pulsed, in a conventional chromium release assay.
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Table 2
Antigen-specific, MHC-restricted CTL activity to native and mutated PyCSP peptide epitopes
Effector Target CTL response
Native (non-mutated) Non-mutated dominant CD8+ 280–288 peptide epitope Yes
280–288 peptide epitope mutated at P2, P9, P10 No
CD8+ 280–288 peptide epitope mutated at P2 Not done
280–288 peptide epitope mutated at P9, P10 Yes
CD4+(57–70)/subdominant CD8+(58–67) peptide epitope No
Mutated P2, P9/P10 Non-mutated CD8+ 280–288 peptide epitope No
280–288 peptide epitope mutated at P2, P9, P10 No
CD8+ 280–288 peptide epitope mutated at P2 Not done
280–288 peptide epitope mutated at P9, P10 No
CD4+(57–70)/subdominant CD8+(58–67) peptide epitope No
Mutated P2 Non-mutated CD8+ 280–288 peptide epitope No
CD8+ 280–288 peptide epitope mutated at P2 Not done
CD8+ 280–288 peptide epitope mutated at P9, P10 No
CD4+(57–70)/subdominant CD8+(58–67) peptide epitope No
Mutated P9, P10 Non-mutated CD8+ 280–288 peptide epitope No
CD8+ 280–288 peptide epitope mutated at P2 No
CD8+ 280–288 peptide epitope mutated at P9, P10 Not done
CD4+(57–70)/subdominant CD8+(58–67) peptide epitope No
MAP 57–70 Non-mutated CD8+ 280–288 peptide epitope No
CD8+ 280–288 peptide epitope mutated at P2, P9, P10 No
CD4+(57–70)/subdominant CD8+(58–67) peptide epitope Yes
BALB/c mice were immunized with non-mutated PyCSP DNA, P2, P9/P10 mutated PyCSP DNA, P2 mutated PyCSP DNA, P9/P10 mutated PyCSP DNA, or a
MAP based on the subdominant CD8+ T cell epitope (residues 58–67) nested in the dominant CD4+ T cell epitope (residues 57–70). Splenocytes were harvested
2 weeks after the third immunization and cultured in vitro for 6 days in the presence of synthetic peptides representing the immunodominant CD8+ T cell epitope
(residues 280–288), the immunodominant CD8+ 280–288 epitope mutated at P2 or at P9/P10, or the subdominant CD8+ epitope (58–67)/dominant CD4+ T cell
epitope (residues 57–70). Effectors were then assayed in a conventional chromium release assay against MHC-matched P815 cells or MHC-mismatched EL4 cells
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tnot shown) target cells pulsed with the respective peptides, or not pulsed.
ot induce CTL responses against the immunodominant CD8+ T
ell epitope (residues 280–288) or the overlapping CD8+/CD4+
pitope (residues 280–295) (Fig. 1 and Table 2), consistent with
he fact that mutation of any of these anchor residues markedly
brogates binding to the H-2Kd MHC molecule (Table 1). These
ffectors also failed to recognize the subdominant CD8+ T cell
pitope at residues 58–67 (Table 2), indicating that responses
ere not skewed towards induction of subdominant CD8+ T
ell responses. That CTL specific for the subdominant epitope
ould be induced by peptide immunization was demonstrated in
arallel (Table 2).
Consistent with the peptide epitope data presented above,
plenocytes of mice immunized with non-mutated PyCSP DNA
timulated in vitrowith P815 cells transfected with the same non-
utated PyCSP plasmid induced Ag-specific CTL (Table 3).
hese CTL recognized the intact protein as expressed in vitro by
lasmid DNA encoding the PyCSP containing the non-mutated
/10-mer epitope as well as the immunodominant CD8+ CTL
pitope (Table 3). In contrast, stimulation with P815 cells trans-
ected with PyCSP DNA containing the CTL epitope mutated
t P2, P9/P10 failed to induce CTL that recognized the intact
rotein or the defined CD8+ CTL epitope (Table 3). The lack of
esponse to the intact protein indicated that there was no induc-
ion of CTL specific for the subdominant epitope nor any other
TL epitope located on the PyCSP. IFAT analysis demonstrated
xpression of both the non-mutated and mutated DNA in P815
n
o
wransfected cells, indicating that the negative CTL results were
ue to a lack of recognition, not a lack of expression. Although
he above data cannot exclude a more subtle failure of the mutant
o be processed for Ag recognition, this possibility is excluded on
he basis of demonstrated lymphoproliferative and Ab responses
see below).
To confirm that the lack of recognition of other epitopes on
he PyCSP was not somehow related to plasmid DNA admin-
stration, mice were immunized with irradiated sporozoites
nd splenocytes evaluated for their capacity to recognize non-
utated (native) and mutated PyCSP protein or peptide epitopes.
porozoite-immune splenocytes stimulated in vitro with P815
ells transfected with the non-mutated PyCSP DNA, or pulsed
ith the synthetic peptide representing the immunodominant
D8+ T cell epitope, induced CTL which recognized both the
ntact protein and the immunodominant CD8+ T cell epitope
Table 3). These CTL failed to recognize the epitope mutated at
ositions P2, P9 and P10, as expressed in vitro by plasmid DNA
ontaining the mutated epitope. Moreover, consistent with the
lasmid DNA studies, sporozoite immune effectors stimulated
n vitrowith PyCSP DNA containing the P2, P9/P10 mutations in
he 280–288 epitope did not recognize the native PyCSP protein,
or the 280–288 epitope (Table 3).
Overall, these data support the importance of the immun-
dominant CD8+ T cell epitope and the P2 primary anchor
ithin this epitope.
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Table 3
Antigen-specific, MHC-restricted CTL activity to native and mutated PyCSP protein
Effector Target CTL response
Native peptide (280–288) Non-mutated dominant CD8+ 280–288 peptide epitope Yes
Native protein Yes
Mutated protein No
Native protein (irradiated sporozoites) Non-mutated dominant CD8+ 280–288 peptide epitope Yes
Native protein Yes
Mutated protein No
Native protein (PyCSP DNA) Non-mutated dominant CD8+ 280–288 peptide epitope Yes
Native protein Yes
Mutated protein No
Mutated protein (P2, P9/P10 mutated DNA) Non-mutated dominant CD8+ 280–288 peptide epitope No
Native protein No
Mutated protein No
Splenocytes from BALB/c mice immunized with non-mutated PyCSP DNA, harvested 2 weeks after the third immunization, were cultured in vitro for 6 days with
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e815 cells transfected with non-mutated or mutated PyCSP DNA or with a s
80–288). Effectors were then assayed in a conventional chromium release a
ransfected with the non-mutated or mutated PyCSP DNA or control DNA, or p
.4. Effect of mutations on IFN-γ and TNF-α responses to
mmunodominant and subdominant epitopes by
ntracellular cytokine staining
Both IFN- and TNF-were produced by CD8+ T cells from
ice immunized with the non-mutated PyCSP plasmid. These
esponses were Ag-specific, and directed to both immunodom-
nant and subdominant CD8+ T cell epitopes PyCSP 280–288,
80–295 and 58–67 (Fig. 2). In contrast, no CD8+ T cell-
ediated Ag-specific IFN- or TNF- responses were detectedo any of those epitopes when effectors were splenocytes from
ice immunized with the mutated construct (Fig. 2). In this
xperiment, consistent with other studies from our laboratory,
D4+ T cell responses induced by immunization with PyCSP
v
c
ig. 2. Antigen-specific IFN- and TNF- responses to immunodominant CD8+ a
nduced by immunization with non-mutated and mutated PyCSP plasmid DNA. IF
ACS analysis. Splenocytes from BALB/c mice immunized with non-mutated or P2,
ere used as effector cells, stimulated in vitro with MHC-matched A20.2J APCs puls
pitopes. Histograms represent the means of three mice per group, pooled.tic peptide representing the immunodominant CD8+ T cell epitope (residues
gainst MHC-matched P815 cells or MHC-mismatched EL4 cells target cells
with or without the CD8+ peptide epitope.
NA and assessed by intracellular staining were low. Nonethe-
ess, those CD4+ T cell responses that were detected (between
.02% and 0.06%) were specific for the PyCSP 57–70, 58–67
nd 59–79 epitopes (not for PyCSP 280–288 or PyCSP 280–295)
nd were detected in both mutated and non-mutated plasmid
mmunized mice (data not shown).
.5. Effect of mutations on IFN-γ ELIspot response to
mmunodominant and subdominant epitopes and
D4+/CD8+ T cell dependenceIn mice immunized with non-mutated PyCSP plasmid, in
itro depletion of CD8+ T cells but not CD4+ T cells, signifi-
antly reduced the IFN- responses to the PyCSP 280–288 and
nd CD8+/CD4+ epitopes and subdominant CD8+ and CD8+/CD4+ epitopes
N- or TNF- cytokines were assayed by intracellular cytokine staining and
P9/P10 mutated PyCSP DNA harvested 4 weeks after the third immunization
ed with synthetic peptides representing defined CD8+ and CD8+/CD4+ T cell
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Fig. 3. T cell dependence of antigen-specific IFN- responses to immunodominant CD8+ and CD8+/CD4+ epitopes and subdominant CD8+ and CD8+/CD4+
epitopes induced by immunization with non-mutated and mutated PyCSP plasmid DNA. Ex vivo IFN- ELIspot was carried out using splenocytes from BALB/c
mice immunized with non-mutated or P2, P9/P10 mutated PyCSP DNA harvested 4 weeks after the third immunization as effector cells, stimulated in vitro with
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IHC-matched A20.2J APCs pulsed with synthetic peptides representing defin
D8+ T cells (CD8−), CD4+ T cells (CD4−) or NK cells (NK−) were carried
resented as spot forming cells (SFC) per million splenocytes for n = 3 mice pe
yCSP 280–295 epitopes (Fig. 3), consistent with published
ata (Sedegah et al., 1994). In contrast, and as expected based
n the literature, IFN- responses to the PyCSP 59–79 epitope
ere dependent on CD4+ T cells but not CD8+ T cells, and the
esponses to the PyCSP 57–70 epitope were dependent on CD4+
cells and partially dependent on CD8+ T cells. Responses to
he subdominant CD8+ T cell epitope PyCSP 58–67 were typ-
cally lower than responses to other epitopes, making it more
ifficult to ascertain significant differences in magnitude, and T
ell subset dependence.
Mutation of the primary anchor completely abrogated the
yCSP-specific CD8+ T cell dependent IFN- responses to
he immunodominant CD8+ T cell epitope (residues 280–288)
nd the overlapping CD8+/CD4+ epitope (residues 280–295)
Fig. 3). However, mutation had no significant effect on the
D8+ T cell dependent IFN- responses to the subdominant
D8+ T cell epitope (residues 58–67) or the CD4+ T cell depen-
ent IFN- responses to the CD4+ T cell epitopes (residues
7–70, 59–79) (Fig. 3). These data confirm that the negative
TL or IFN- responses to the immunodominant 280–288/289
pitope were due to a lack of recognition of the mutated plasmid,
ot a lack of expression.
.6. Effect of mutations on lymphoproliferative response to
mmunodominant and subdominant epitopes
As expected, mutation of the primary anchor residues of the
mmunodominant PyCSP CD8+ T cell epitope did not abro-
ate the lymphoproliferative responses to the defined CD4+
cell epitopes (residues 57–70, 59–79) or the overlapping
D8+/CD4+ epitope (residues 280–295); responses were com-
arable to those induced by non-mutated PyCSP (Fig. 4A).
owever, there was a trend in at least one experiment to more
obust CD4+ proliferative T cell responses in mice immunized
ith PyCSP constructs in which the primary anchor residue of
he vaccine (P2) had been mutated (P2; P2,P9/P10), as com-
i
r
P
(8+ and CD8+/CD4+ T cell epitopes. Where indicated, in vitro depletions of
splenocyte suspensions immediately prior to ELIspot (see Section 2). Data are
p, pooled.
ared to the non-mutated plasmids (Fig. 4B). These data are
onsistent with a scenario where immune responses induced by
utated PyCSP plasmids may be deviated from a CD8+ type 1
esponse towards a CD4+ T cell response.
.7. Effect of mutations on PyCSP specific antibody
esponse
Anti-PyCSP specific Ab responses were induced by all
utated PyCSP constructs (P2; P9/P10; and P2, P9/P10)
s well as the non-mutated PyCSP plasmid (Fig. 5). How-
ver, in two independent experiments, Ab titers (OD units
.5) in mice vaccinated with mutated P2, P9/P10 PyCSP
n = 14 tested individually, mean ± S.D. = 12,764 ± 5827)
ere significantly higher compared to non-mutated PyCSP
n = 16, mean ± SD = 6393 ± 3498) after three immunizations
p < 0.002). This difference was also noted with samples col-
ected after the first and second immunizations (Fig. 5). Thus,
t appears that when T cell responses to the immunodominant
D8+ T cell epitope are eliminated, there is a significant
ncrease in Ag-specific Ab responses, These data provide
dditional support for our hypothesis that immune responses
nduced by mutated PyCSP plasmids may be deviated from a
redominantly CD8+ Tc1 profile towards a CD4+ Th type that
ould favor Ab production.
.8. Effect of mutations on cytokine secretion in serum
amples
Multiplexed cytokine assays showed no difference between
utated and non-mutated groups for the Th1 type cytokines
FN-, TNF-, IL-2, IL-12, IL-18, IL-1, and IL-1. However,
ncreased responses in constructs with a mutated P2 anchor
esidue as compared to constructs with the native residue at
2 were noted for the following Th2 type cytokines [median
25%, 75%)]: IL-4, 63 (49, 93) versus 48 (34, 65), p = 0.028
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Fig. 4. Lymphoproliferative responses to immunodominant and subdominant CD4+ or CD4+/CD8+T cell epitopes induced by immunization with non-mutated and
m mutat
4 in vitr
e T ce
a t othe
(
1
T
f
i
3
w
a
(
p
s
w
s
p
(
N
t
m
o
t
D
i
a
t
m
P
m
2
t
t
a
D
t
n
t
iutated plasmid DNA. Splenocytes from BALB/c mice immunized with non-
weeks after the third immunization (n = 3 per group, pooled), and stimulated
pitope 57–70, CD4+/CD8+ T cell epitope 280–295, or the subdominant CD4+
nd cell concentration of 125,000 cells per well. Similar results were obtained a
Mann–Whitney U-test); IL-6, 188 (75, 325) versus 67 (37,
83), p = 0.028; IL-10, 85 (32, 133) versus 58 (17, 94), p = 0.140.
here was no effect on IL-13. Data are consistent with a shift
rom a Th1 profile towards Th2 responses when the P2 residue
s mutated.
.9. Effect of mutations on sterile protective immunity
Consistent with previous studies, 48.1% sterile protection
as obtained in BALB/c mice following immunization with
plasmid DNA construct encoding the non-mutated PyCSP
Table 4). Mutation at P9 and P10 representing the C-terminus
rimary anchor residues had no apparent effect on protection,
ince 52.0% sterile protection was obtained in mice immunized
ith the mutated P9/P10 construct (p = 1.0, non-mutated ver-
us P9/P10 mutated) and there was no observable delay in the
repatent period as compared with the non-mutated construct
data not presented). In contrast, data demonstrated that the
-terminus primary anchor residue at P2 was important for pro-
ective efficacy since mutation of the P2 position, with or without
utation of P9/P10 positions, decreased the protection to a level
f 25.9–33.3% (p = 0.16). These data support the importance of
t
e
I
Ced PyCSP or mutated P2, P9/P10 or P2/P1/P10 PyCSP plasmids harvested at
o with synthetic peptides representing defined immunodominant CD4+ T cell
ll epitope 59–79. Data is presented at a peptide concentration of 10g/ml (A)
r cell and peptide concentrations (not shown).
he immunodominant CD8+ T cell epitope 280–288 in PyCSP
NA vaccine induced protection (Sedegah et al., 1994), and the
mportance of the N-terminal but not the C-terminal primary
nchors.
Interestingly, however, significant sterile protection relative
o the controls was obtained in mice immunized with plas-
id DNA mutated at either position P2 only, or positions
2 and P9/P10 (Table 4). Although protective immunity was
arkedly reduced by mutation of the primary P2 anchor of the
80–288/289 epitope, it was not completely abrogated despite
hat this epitope is the only immunodominant CTL epitope iden-
ified on the PyCSP, and that CTL specific for this epitope can
doptively transfer protection. Thus, mice immunized with a
NA vaccine that elicits CD8+ T cell responses specific for
he immunodominant CD8+ T cell epitope, and mice immu-
ized with a vaccine that cannot produce CD8+ T cells against
hat epitope, are both significantly protected against Plasmod-
um sporozoite challenge. However, the immunity elicited in
he absence of CD8+ T cell responses to the immunodominant
pitope is not as robust as in the presence of effective CD8+
FN- effector responses directed against the immunodominant
D8+ T cell epitope, since the level of protective efficacy and
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Table 4
Sterile protection against sporozoite challenge induced by immunization with plasmid DNA constructs
Immunogen Sequence Number of protected/challenged %Protection p-Value (relative to
non-mutated)
p-Value (relative
to control)
Negative control – 0/25a 0 –
PyCSP native (non-mutated) SYVPSAEQIL 13/27 48.1 – 0.0001
PyCSP mutated P2b SAVPSAEQI 7/27 25.9 0.16 0.0062
PyCSP mutated P9/P10 SYVPSAEQAA 13/25 52.0 0.78 <0.0001
PyCSP mutated P2, P9/P10 SAVPSAEQAA 8/24 33.3 0.28 0.0017
P2 mutations (7/27 + 8/24) 15/51 29.4 0.10 0.0025
Any mutations (7/27 + 13/25 + 8/24) 28/76 36.8 0.30 0.0004
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ta All naive mice (9 mice) and all control mice immunized with vector DNA c
b Site-directed mutagenesis was carried out using the QuikChangeTM Site-Di
verall immune responses are lower. Overall, these data indicate
hat immune effector mechanisms distinct from those directed
gainst the CD8+ 280–288 epitope are capable of conferring
terile protective immunity, albeit not as robust as in the pres-
nce of CD8+ T cell responses, and are consistent with a scenario
f immune deviation as indicated above.
.10. Effect of mutations on liver stage parasite burden in
ivo
Consistent with the sterile protection reported above, signifi-
ant partial protection as measured by a reduction in liver-stage
arasite burden by TaqManTM RT-PCR was noted in BALB/c
ice immunized with the non-mutated PyCSP DNA vaccine
geometric mean [95% CI] P. yoelii 18S rRNA/mouse GAPDH,
on-mutated 0.0013 [0.0008, 0.0028] versus control plasmid
.0087 [0.0040, 0.0191], p = 0.0009, calculated by Student’s
-test on log transformed values). As expected, this was signif-
cantly abrogated by in vivo depletion of effector CD8+ T cells
rior to challenge (0.0257 [0.0117, 0.0566], p < 0.0001). Also
onsistent with the results of studies using blood-stage para-
itemia as the read-out of protection, and the importance of the
mmunodominant CD8+ T cell epitope, mutation at positions P2,
9/P10 in the PyCSP 280–288 epitope significantly abrogated
he PyCSP DNA vaccine-induced protection (0.0170 [0.0044,
.0669], p = 0.0039).
Consistent with the trend for deviation of the effector immune
esponse from a CD8+ Tc1 profile to a CD4+ Th profile with
utation of the primary anchor residues described above, a dif-
erent pattern of CD4+/CD8+ T cell dependence was noted in
ice immunized with the mutated compared to the non-mutated
yCSP constructs. Specifically, there was a significant differ-
nce in the effect of CD8+ depletion in mice immunized with
he mutated versus non-mutated plasmid (0.0076 [0, 0.0191],
= 0.0124); partial protection after in vivo depletion of CD8+ T
ells in the mutated group was not significantly different from
hat achieved in the undepleted non-mutated group (p = 0.1972).
n contrast, in vivo depletion of either CD4+ T cells or IFN-
significantly abrogated protection as compared to the levels
chieved by immunization with non-mutated plasmid (0.0234
0, 0.0489], p = 0.0004 and 0.0298 [0, 0.0631], p < 0.0001,
espectively). Overall, data demonstrate that IFN- dependent
rotective immunity directed at the liver stage can be induced
a
c
v
eing an unrelated insert (16 mice) became infected.
Mutagenesis kit (Stratagene), as described by the manufacturer.
y vaccination with plasmid DNA constructs where the encoded
mmunodominant CD8+ T cell epitope is mutated to abrogate
inding to the class I MHC, but that this protection is signifi-
antly reduced as compared to immunization with non-mutated
onstructs, and is mediated by CD4+ T cells rather than CD8+
cells.
. Discussion
We have previously demonstrated that the protective immu-
ity induced by immunization with plasmid DNA encoding
yCSP is absolutely dependent on CD8+ T cells and IFN-
ut not CD4+ T cells (Doolan et al., 1996a; Sedegah et al.,
994). Other studies have identified a single immunodominant
D8+ T cell epitope on PyCSP, at residues 280–288 (Weiss et
l., 1990). Herein, we evaluated the effect of selectively mutat-
ng this single immunodominant CD8+ T cell epitope on the
mmunogenicity and protective immunity induced by PyCSP
NA vaccines in mice. This approach allowed us to elucidate the
ole of immunodominant versus subdominant CD8+ T cell epi-
opes in protection against P. yoelii sporozoite challenge induced
y DNA vaccination, and to further dissect the relative contribu-
ion of CD4+ versus CD8+ T cells in the effector mechanisms
f pre-erythrocytic stage immunity.
Our data shows that the immunodominant PyCSP 280–288
pitope is absolutely required for optimal protection against
alaria induced by immunization with PyCSP DNA. Further-
ore, recognition of the non-mutated and P9/P10 mutated
lasmid and 10-mer peptide shows that the P2 N-terminus
rimary anchor residue, but not P9 or P10 C-terminus pri-
ary anchor residues, of this epitope is critical for CD8+
cell recognition. CTL specific for this 9-mer epitope can
doptively transfer protection, and site-directed mutagenesis of
he epitope abrogates the CTL response (Weiss et al., 1988).
nterestingly, the P. yoelii and the P. berghei CTL epitopes
ave identical residues at anchor positions: PyCSP (280–289)
SYVPSAEQIL) and PbCSP (249–260) (NDDSYIPSAEKI). It
as been shown that a CD8+ CTL clone induced by immuniza-
ion withP. yoelii irradiated sporozoites recognizes both epitopes
nd protects mice against both P. yoelii and P. berghei sporozoite
hallenge upon adoptive transfer (Weiss et al., 1992). This pro-
ides further evidence for the importance of the PyCSP 280–288
pitope and the conservation of the anchor amino acids in the
2246 C. Doban˜o et al. / Molecular Immu
Fig. 5. Antibody responses induced by immunization with non-mutated and
mutated PyCSP plasmids, detected by ELISA against recombinant full length
PyCSP. Data show results with pooled sera (n = 10) collected 12 days after
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ncluding results from two separate experiments (Expt. 1 and Expt. 2) and all
accine constructs.
rotective immunity induced by immunization with PyCSP and
rradiated sporozoite vaccines in mice.
Consistent with data from the protection studies, in vivo and in
itro immunogenicity data showed that IFN- responses induced
y PyCSP DNA vaccination were directed predominantly to the
ingle immunodominant CD8+ T cell epitope, that these IFN-
immune responses were dependent on CD8+ T cells but not
D4+ or NK cells, and that the P2 (but not P9/P10) primary
nchor residue is critical. Mutation of this residue completely

5
l
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brogated the CD8+ PyCSP-specific CTL activity and CD8+
cell dependent IFN- and TNF- responses to the immun-
dominant CD8+ T cell epitope (residues 280–288) and the
verlapping CD8+/CD4+ epitope (residues 280–295). The lack
f detectable response to the intact protein in the absence of a
pecific response to the 280–288/289 epitope suggests that there
as no induction of CTL specific for any other epitopes on the
yCSP Ag, including the subdominant CD8+ T cell epitope
ocated at residues 58–67 or CD4+ T cell epitopes. Cytokine
nd lymphoproliferative T cell responses to other epitopes and
b responses to the intact protein exclude the possibility that
egative CD8+ T cell-mediated responses with the mutant plas-
id were due to a failure in Ag processing and recognition, or
lack of expression.
Nonetheless, mutation of the P2 anchor residue of the
80–289 epitope, or the P2, P9/P10 anchors associated with
HC binding inhibited but did not completely abrogate protec-
ive immunity againstP. yoelii in mice, despite that this epitope is
he only immunodominant Kd restricted CTL epitope identified
n the PyCSP. These data suggest that when the immunodomi-
ant CD8+ T cell response is eliminated, liver-stage protection
s mediated by effector cells specific for a T cell epitope(s) dis-
inct from the immunodominant CD8+ T cell epitope and/or by
different effector mechanism.
In a given protein Ag, there is a hierarchy of T cell epi-
opes, originally defined by Sercarz and co-workers (Gammon
t al., 1987). Those epitopes eliciting the greatest immune
esponses following protein or peptide immunization are termed
mmunodominant. Those epitopes stimulating weaker and more
ariable responses following protein immunization, with strong
esponses being induced by peptide immunization, are termed
ubdominant. Subdominant epitopes are generated by natural
g processing, and T cells elicited by peptide immunization
an recognize intact protein. Other epitopes that are not recog-
ized following immunization with the intact protein but that are
evertheless immunogenic and to which responses are induced
y peptide immunization are termed cryptic. Cryptic epitopes
re capable of binding the MHC but are not naturally processed
y the immune system, or are processed at subthreshold levels. T
ells specific for these cryptic epitopes are present in the normal
cell repertoire, and may become visible to the immune system
nder certain conditions.
In this context, it is possible that abrogation of the protective
mmunity directed against the immunodominant CTL epitope
eveals protective effector cells directed against an epitope previ-
usly presented subdominantly or cryptically. Our data demon-
trate that the suboptimal protection induced by immunization
ith mutated PyCSP DNA is mediated by effector cells specific
or T cell epitopes distinct from the immunodominant CD8+ T
ell epitope, including but not restricted to the previously defined
D4+ T cell epitopes (residues 57–70, 59–79). Immunogenic-
ty data showed that mutation of the primary anchor residues
ad no significant effect on the CD8+ T cell dependent IFN-
responses to the subdominant CD8+ T cell epitope (residues
8–67) but did enhance the CD4+ T cell dependent lymphopro-
iferative responses to the CD4+ T cell epitopes (residues 57–70,
9–79), and the Ab responses to recombinant PyCSP.
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Liver-stage protection and in vivo depletion studies showed
hat the partial protection induced by immunization with mutated
lasmid was mediated by CD4+ T cells, rather than by CD8+
cells. This indicates that, in this system, the effector function
f Ag-specific CD4+ T cells (involving secretion of IFN-) is
elatively more important than CD8+ effector T cells directed
gainst an epitope presented subdominantly.
We interpret our data as consistent with the scenario of
mmune deviation (Parish, 1996) where, when the immunodom-
nant CD8+ T cell epitope is rendered non-functional, effector
esponses are deviated from a CD8+ IFN- dependent pro-
le to a CD4+ T cell IFN- dependent helper profile with
nhanced CD4+ lymphoproliferative responses and enhanced
b responses. Results of IFN- ELIspot, intracellular cytokine
taining, lymphoproliferation and Ab immunogenicity assays,
n vivo liver-stage and blood-stage protection assays, as well as
n vitro and in vivo depletions of effector CD4+ and CD8+ T
ells are consistent with this hypothesis. In particular, the sig-
ificantly higher Ab titers are indicative of the induction of a
ore robust CD4+ Th effector function by immunization with
NA plasmids in which the primary anchor residues involved
n binding to the class I MHC molecules have been mutated.
Overall, data suggested that the protective immune responses
nduced by DNA vaccination are directed predominantly against
mmunodominant CD8+ T cell epitopes, and that although
esponses can be induced against other epitopes including CD4+
cell epitopes, these responses are poor and not adequate for
ptimal protection against parasite challenge.
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